Healthcare Business News

Johnson & Johnson selling blood testing unit for $4.15B

By Jaimy Lee
Posted: January 16, 2014 - 2:30 pm ET

Johnson & Johnson plans to divest its blood-testing business to the Carlyle Group for $4.15 billion.

The New Brunswick, N.J.-based company said in early 2013 that it was exploring strategic alternatives for its ortho-clinical diagnostics business.

The acceptance period for the Carlyle Group's bid ends March 31. If the deal is accepted by Johnson & Johnson, it is expected to close in mid-2014.

Advertisement | View Media Kit


The Carlyle Group, a Washington-based private equity firm, cited “rising demand for sophisticated medical diagnostic products and services worldwide” as a contributing factor in its interest in the Johnson & Johnson business unit, which is based in Raritan, N.J.

The business provides a range of services, including prenatal testing and diagnostics for anemia, thyroid and metabolic diseases and cardiac conditions. Johnson & Johnson Chairman and CEO Alex Gorsky last year said the diagnostics business did not have a No. 1 or No. 2 position in its market.

Johnson & Johnson is expected to provide more information about the divestiture next week when it releases its end-of-year financial results.

Follow Jaimy Lee on Twitter: @MHjlee

What do you think?

Share your opinion. Send a letter to the Editor or Post a comment below.

Post a comment

Loading Comments Loading comments...



Switch to the new Modern Healthcare Daily News app

For the best experience of on your iPad, switch to the new Modern Healthcare app — it's optimized for your device but there is no need to download.